TLDR: Therna Biosciences has officially launched, introducing a groundbreaking biology-guided, AI-powered platform aimed at revolutionizing the development of RNA medicines. The company seeks to engineer programmable RNA therapeutics with enhanced translation, durability, immune evasion, and precise tissue targeting, backed by a $10 million seed funding round.
San Francisco, CA – August 26, 2025 – Therna Biosciences today announced its formal launch, setting a new course for the development of RNA medicines through its innovative biology-guided, AI-powered platform. The company’s core vision is to decode the intricate language of RNA to pioneer programmable RNA therapeutics, designed for superior performance in areas such as enhanced translation, extended durability, effective immune evasion, and highly precise tissue targeting. This advancement promises to unlock unprecedented levels of safety, efficacy, and therapeutic potential in the field of medicine.
Founded by Hani Goodarzi, Ph.D., a distinguished investigator at UCSF and Arc Institute with over a decade of expertise in RNA biology and advanced generative AI, Therna is committed to building the largest generative RNA models to date. Dr. Goodarzi emphasized the foundational approach, stating, “By grounding our approach in RNA biology itself and applying AI to deeply interpret RNA’s code, we can design fit-for-purpose RNAs that perform better than native RNA, efficiently translated, long-lasting, and capable of homing to specific tissues and cells.”
Nazli Azimi, Ph.D., co-founder and CEO of Therna, highlighted the timely nature of their endeavor. “AI is reaching an inflection point in its application to biological design,” said Dr. Azimi. She further elaborated on the company’s operational efficiency, noting, “At Therna, we have created a platform that radically accelerates the development of RNA medicines, enabling a lab-in-the-loop cycle that produces better molecules, with fewer iterations. Our deep expertise in drug development and clinical strategy gives us a clear path to translate these discoveries into meaningful clinical impact.” This ‘lab-in-the-loop’ process involves AI generating novel RNA sequences, which are then validated through laboratory experiments, with the results feeding back to retrain and enhance the AI model’s predictive capabilities.
Therna Biosciences has successfully secured a $10 million seed funding round, demonstrating strong investor confidence in its transformative potential. The round was led by prominent venture capital firms AIX Ventures, Pear VC, and Fusion Fund. This capital will be instrumental in advancing the company’s platform and developing a robust pipeline of next-generation RNA therapeutics. Krish Ramadurai, Partner at AIX Ventures, commented on the strategic importance of Therna’s work: “The convergence of AI and RNA biology marks a paradigm shift in drug development. Therna’s differentiated approach of combining proprietary AI models with deep biological insight positions it to be a category-defining company in programmable RNA medicines.”
Also Read:
- Nugen Secures Pre-Seed Funding to Advance Reliable AI for Enterprise Applications
- EPAM Outlines Framework for AI-Driven R&D Transformation in Life Sciences
Therna’s proprietary generative RNA design platform represents a significant breakthrough in biotech innovation. By dramatically accelerating the design cycle and enabling programmable drug properties, the platform is poised to address diseases previously considered beyond the reach of traditional therapeutic modalities. This technology places Therna at the forefront of a new era in medicine, with vast commercial potential across multiple therapeutic areas.
